These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 38401907)

  • 1. Cost-Effectiveness and the Economics of Genomic Testing and Molecularly Matched Therapies.
    Banerjee S
    Surg Oncol Clin N Am; 2024 Apr; 33(2):231-242. PubMed ID: 38401907
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genomic profiling in oncology clinical practice.
    Rodríguez N; Viñal D; Rodríguez-Cobos J; De Castro J; Domínguez G
    Clin Transl Oncol; 2020 Sep; 22(9):1430-1439. PubMed ID: 31981077
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Next generation sequencing in cancer: opportunities and challenges for precision cancer medicine.
    Paolillo C; Londin E; Fortina P
    Scand J Clin Lab Invest Suppl; 2016; 245():S84-91. PubMed ID: 27542004
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Integrating genomics into clinical oncology: ethical and social challenges from proponents of personalized medicine.
    McGowan ML; Settersten RA; Juengst ET; Fishman JR
    Urol Oncol; 2014 Feb; 32(2):187-92. PubMed ID: 24445286
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Empowering effective biomarker-driven precision oncology: A call to action.
    Lawler M; Keeling P; Kholmanskikh O; Minnaard W; Moehlig-Zuttermeister H; Normanno N; Philip R; Popp C; Salgado R; Santiago-Walker AE; Trullas A; van Doorn-Khosrovani SBVW; Vart R; Vermeulen J; Vitaloni M; Verweij J
    Eur J Cancer; 2024 Sep; 209():114225. PubMed ID: 39053288
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A personalized paradigm in the treatment of platinum-resistant ovarian cancer - A cost utility analysis of genomic-based versus cytotoxic therapy.
    Wallbillich JJ; Forde B; Havrilesky LJ; Cohn DE
    Gynecol Oncol; 2016 Jul; 142(1):144-149. PubMed ID: 27106017
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical and Technical Aspects of Genomic Diagnostics for Precision Oncology.
    Sheikine Y; Kuo FC; Lindeman NI
    J Clin Oncol; 2017 Mar; 35(9):929-933. PubMed ID: 28297627
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enabling Precision Oncology Through Precision Diagnostics.
    Brown NA; Elenitoba-Johnson KSJ
    Annu Rev Pathol; 2020 Jan; 15():97-121. PubMed ID: 31977297
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The evidence for expanded genetic testing for pediatric patients with cancer.
    Maese L; Schiffman JD
    Future Oncol; 2018 Feb; 14(3):187-190. PubMed ID: 29327612
    [No Abstract]   [Full Text] [Related]  

  • 10. Universal Genomic Testing: The next step in oncological decision-making or a dead end street?
    Holch JW; Metzeler KH; Jung A; Riedmann K; Jost PJ; Weichert W; Kirchner T; Heinemann V; Westphalen CB
    Eur J Cancer; 2017 Sep; 82():72-79. PubMed ID: 28648701
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interpreting and integrating genomic tests results in clinical cancer care: Overview and practical guidance.
    Casolino R; Beer PA; Chakravarty D; Davis MB; Malapelle U; Mazzarella L; Normanno N; Pauli C; Subbiah V; Turnbull C; Westphalen CB; Biankin AV
    CA Cancer J Clin; 2024; 74(3):264-285. PubMed ID: 38174605
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of precision medicine in the fourth-line treatment of metastatic lung adenocarcinoma: An early decision analytic model of multiplex targeted sequencing.
    Doble B; John T; Thomas D; Fellowes A; Fox S; Lorgelly P
    Lung Cancer; 2017 May; 107():22-35. PubMed ID: 27316470
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genomic medicine and risk prediction across the disease spectrum.
    Kotze MJ; Lückhoff HK; Peeters AV; Baatjes K; Schoeman M; van der Merwe L; Grant KA; Fisher LR; van der Merwe N; Pretorius J; van Velden DP; Myburgh EJ; Pienaar FM; van Rensburg SJ; Yako YY; September AV; Moremi KE; Cronje FJ; Tiffin N; Bouwens CS; Bezuidenhout J; Apffelstaedt JP; Hough FS; Erasmus RT; Schneider JW
    Crit Rev Clin Lab Sci; 2015; 52(3):120-37. PubMed ID: 25597499
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Translating genomics in cancer care.
    Bombard Y; Bach PB; Offit K
    J Natl Compr Canc Netw; 2013 Nov; 11(11):1343-53. PubMed ID: 24225968
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cascade testing for hereditary cancer in Singapore: how population genomics help guide clinical policy.
    Caeser R; Chiang J; Tan ES; Tai ES; Ngeow J
    Fam Cancer; 2024 Jun; 23(2):133-140. PubMed ID: 38662262
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tearing down the walls: FDA approves next generation sequencing (NGS) assays for actionable cancer genomic aberrations.
    Allegretti M; Fabi A; Buglioni S; Martayan A; Conti L; Pescarmona E; Ciliberto G; Giacomini P
    J Exp Clin Cancer Res; 2018 Mar; 37(1):47. PubMed ID: 29506529
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Required Human and System Resources for Genomic Medicine].
    Aimono E; Nishihara H
    Yakugaku Zasshi; 2020; 140(5):651-655. PubMed ID: 32378666
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness analyses of genetic and genomic diagnostic tests.
    Payne K; Gavan SP; Wright SJ; Thompson AJ
    Nat Rev Genet; 2018 Apr; 19(4):235-246. PubMed ID: 29353875
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness analysis of universal germline testing for patients with pancreatic cancer.
    Krepline AN; Geurts JL; George B; Kamgar M; Madhavan S; Erickson BA; Hall WA; Griffin MO; Evans DB; Tsai S; Kim RY
    Surgery; 2021 Mar; 169(3):629-635. PubMed ID: 32826069
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Considerations of developing an NGS assay for clinical applications in precision oncology: The NCI-MATCH NGS assay experience.
    Lih CJ; Takebe N
    Curr Probl Cancer; 2017; 41(3):201-211. PubMed ID: 28625332
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.